Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy

BMJ Case Reports

Volumn 2015, Issue , 2015, Pages

  Ahmed, Tauqeer ^a   Pandey, Ritwik ^a   Shah, Bhavini ^a   Black, Jason ^a  

^a Liz Plummer Cancer Care Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; COTRIMOXAZOLE; GAMMA GLUTAMYLTRANSFERASE; IPILIMUMAB; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; THYMOCYTE ANTIBODY; VALACICLOVIR; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING DISORDER; CASE REPORT; CAUCASIAN; COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES SCALE; CYTOMEGALOVIRUS INFECTION; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; FEVER; FULMINANT HEPATIC FAILURE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE MUTATION; HUMAN; HYPOTENSION; LETHARGY; LIVER CELL DAMAGE; LIVER EXAMINATION; LYMPHOCYTE COUNT; MALAISE; METASTATIC MELANOMA; MIDDLE AGED; ONCOGENE N RAS; PANCREAS INJURY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RATING SCALE; SINUS BRADYCARDIA; TOXIC HEPATITIS; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ANALOGS AND DERIVATIVES; ANIMAL; AUSTRALIA; DRUG-INDUCED LIVER INJURY; HEPATITIS; HORSE; MELANOMA; SECONDARY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; AUSTRALIA; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATITIS; HORSES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MELANOMA; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 84938946971     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2014-208102     Document Type: Article

References (16)

1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.
2. Australian Institute of Health and Welfare & Australasian Association of Cancer Registries 2012. Cancer in Australia: an overview. Cancer series no. 74. Cat. No. CAN 70. Canberra: AIHW, 2012.
3. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
4. Johnson DB, Saranga-Perry V, Lavin PJ, et al Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 2014 (epub ahead of print) 10.1200/JCO.2013.51.1683
5. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
6. Ibrahim R, Berman D, de Pril V, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol 2011;29: abstract no. 8583.
7. Teschke R, Wolff A, Frenzel C, et al. Drug and herb induced liver injury: council for International Organizations of Medical Sciences scale for causality assessment. World J Hepatol 2014;6:17-32.
8. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998;66:29-37.
9. Chmiel KD, Suan D, Liddle C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 2011;29:e237-40.
10. Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) 2013;2013:857519.
11. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007;13(22 Pt 1):6681-8.
12. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-7.
13. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010;21:1712-17.
14. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
15. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in nelanoma. N Engl J Med 2013;369:134-44.
16. New drugs at FDA: CDER's new molecular entities and new therapeutic biological products of 2014. Silver Spring, MD: Food and Drug Administration. http://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/default.htm